{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:04:12Z","timestamp":1786115052726,"version":"build-2736575974"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01DK13593701A1"],"award-info":[{"award-number":["R01DK13593701A1"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.cgh.2026.06.008","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T16:30:08Z","timestamp":1781713808000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Adjunctive GLP1 Receptor Agonists in Patients With Inflammatory Bowel Diseases and Obesity and\/or Diabetes: A Target Trial Emulation"],"prefix":"10.1016","author":[{"given":"Kuan-Hung","family":"Yeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhruv","family":"Ahuja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagar B.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronghui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo-Kyung","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilherme Piovezani","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talha","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manreet","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Bering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina Y.","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vipul","family":"Jairath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shane W.","family":"Goodwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2640-7269","authenticated-orcid":false,"given":"Siddharth","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2026.06.008_bib1","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nrgastro.2016.181","article-title":"Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes","volume":"14","author":"Singh","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.06.008_bib2","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.cgh.2021.06.049","article-title":"Obesity is associated with increased risk of Crohn's disease, but not ulcerative colitis: a pooled analysis of five prospective cohort studies","volume":"20","author":"Chan","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.06.008_bib3","doi-asserted-by":"crossref","first-page":"630","DOI":"10.14309\/ajg.0000000000000197","article-title":"Impact of obesity on disease activity and patient-reported Outcomes measurement information system (PROMIS) in inflammatory bowel diseases","volume":"114","author":"Jain","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2026.06.008_bib4","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1007\/s10620-025-09052-5","article-title":"Obesity is associated with inferior clinical treatment outcomes in inflammatory bowel disease: a nationwide Dutch registry study","volume":"70","author":"Oomkens","year":"2025","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2026.06.008_bib5","doi-asserted-by":"crossref","first-page":"832","DOI":"10.14309\/ajg.0000000000000608","article-title":"Effect of lifestyle factors on outcomes in patients with inflammatory bowel diseases","volume":"115","author":"Rozich","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2026.06.008_bib6","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1053\/j.gastro.2023.06.036","article-title":"Higher intra-abdominal visceral adipose tissue mass is associated with lower rates of clinical and endoscopic remission in patients with inflammatory bowel diseases initiating biologic therapy: results of the constellation study","volume":"165","author":"Yarur","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2026.06.008_bib7","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s40259-022-00522-0","article-title":"Impact of obesity on response to biologic therapies in patients with inflammatory bowel diseases","volume":"36","author":"Bassi","year":"2022","journal-title":"BioDrugs"},{"key":"10.1016\/j.cgh.2026.06.008_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195123","article-title":"Obesity and response to anti-tumor necrosis factor-alpha agents in patients with select immune-mediated inflammatory diseases: a systematic review and meta-analysis","volume":"13","author":"Singh","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.cgh.2026.06.008_bib9","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1093\/ibd\/izaf098","article-title":"Unravelling the relationship between obesity and inflammatory bowel disease","volume":"31","author":"Sun","year":"2025","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2026.06.008_bib10","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1111\/bjd.17741","article-title":"Does weight loss reduce the severity and incidence of psoriasis or psoriatic arthritis? A critically appraised topic","volume":"181","author":"Mahil","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.cgh.2026.06.008_bib11","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjaf167","article-title":"Glucagon-like peptide (GLP-1) receptor agonists in inflammatory bowel disease: mechanisms, clinical implications, and therapeutic potential","volume":"19","author":"Colwill","year":"2025","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.cgh.2026.06.008_bib12","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.14309\/ajg.0000000000003208","article-title":"Safety and effectiveness of glucagon-like peptide-1 receptor agonists in inflammatory bowel disease","volume":"120","author":"Anderson","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2026.06.008_bib13","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1007\/s10620-025-08964-6","article-title":"Tolerability and effectiveness of glucagon-like peptide-1 receptor agonists in patients with inflammatory bowel disease","volume":"70","author":"Clarke","year":"2025","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2026.06.008_bib14","doi-asserted-by":"crossref","first-page":"3476","DOI":"10.1007\/s10620-025-09344-w","article-title":"Glucagon-like peptide-1 receptor agonist therapy does not increase gastrointestinal adverse events in patients with inflammatory bowel disease","volume":"70","author":"Weng","year":"2025","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2026.06.008_bib15","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjae160","article-title":"GLP-1 analog use is associated with improved disease course in inflammatory bowel disease: a report from the epi-IIRN","volume":"19","author":"Gorelik","year":"2025","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.cgh.2026.06.008_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100979","article-title":"GLP-1 based therapies and disease course of inflammatory bowel disease","volume":"37","author":"Villumsen","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.cgh.2026.06.008_bib17","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1001\/jama.2025.13350","article-title":"Transparent reporting of observational studies emulating a target trial-the TARGET statement","volume":"334","author":"Cashin","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.cgh.2026.06.008_bib18","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1377\/hlthaff.2014.0038","article-title":"Optum Labs: building a novel node in the learning health care system","volume":"33","author":"Wallace","year":"2014","journal-title":"Health Aff (Millwood)"},{"key":"10.1016\/j.cgh.2026.06.008_bib19","doi-asserted-by":"crossref","first-page":"402","DOI":"10.7326\/ANNALS-24-01871","article-title":"The target trial framework for causal inference from observational data: why and when is it helpful?","volume":"178","author":"Hernan","year":"2025","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cgh.2026.06.008_bib20","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1093\/ibd\/izad053","article-title":"Development and validation of claims-based definitions to identify incident and prevalent inflammatory bowel disease in administrative healthcare databases","volume":"29","author":"Dawwas","year":"2023","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2026.06.008_bib21","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1016\/j.spinee.2014.04.025","article-title":"Limitations of administrative databases in spine research: a study in obesity","volume":"14","author":"Golinvaux","year":"2014","journal-title":"Spine J"},{"key":"10.1016\/j.cgh.2026.06.008_bib22","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.thromres.2015.01.012","article-title":"Improving accuracy of International Classification of Diseases codes for venous thromboembolism in administrative data","volume":"135","author":"Sanfilippo","year":"2015","journal-title":"Thromb Res"},{"key":"10.1016\/j.cgh.2026.06.008_bib23","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s12874-021-01440-5","article-title":"Major adverse cardiovascular event definitions used in observational analysis of administrative databases: a systematic review","volume":"21","author":"Bosco","year":"2021","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.cgh.2026.06.008_bib24","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1136\/amiajnl-2012-001557","article-title":"ICD-9 tobacco use codes are effective identifiers of smoking status","volume":"20","author":"Wiley","year":"2013","journal-title":"J Am Med Inform Assoc"},{"key":"10.1016\/j.cgh.2026.06.008_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v042.i08","article-title":"MatchIt: nonparametric preprocessing for parametric causal inference","volume":"42","author":"Ho","year":"2011","journal-title":"J Stat Softw"},{"key":"10.1016\/j.cgh.2026.06.008_bib26","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/aje\/kwaa044","article-title":"Estimating risk ratios and risk differences using regression","volume":"189","author":"Naimi","year":"2020","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.cgh.2026.06.008_bib27","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.13172","article-title":"GLP-1 receptor agonist discontinuation among patients with obesity and\/or type 2 diabetes","volume":"7","author":"Do","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.cgh.2026.06.008_bib28","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.57349","article-title":"Discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists among US adults with overweight or obesity","volume":"8","author":"Rodriguez","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.cgh.2026.06.008_bib29","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/S0140-6736(24)00351-9","article-title":"Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials","volume":"403","author":"Shi","year":"2024","journal-title":"Lancet"},{"issue":"Suppl 2","key":"10.1016\/j.cgh.2026.06.008_bib30","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/dom.16364","article-title":"Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies","volume":"27","author":"Thomsen","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.cgh.2026.06.008_bib31","doi-asserted-by":"crossref","first-page":"4018","DOI":"10.1038\/s41467-020-17840-y","article-title":"Gut microbial co-abundance networks show specificity in inflammatory bowel disease and obesity","volume":"11","author":"Chen","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.cgh.2026.06.008_bib32","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1126\/science.aar3318","article-title":"Hyperglycemia drives intestinal barrier dysfunction and risk for enteric infection","volume":"359","author":"Thaiss","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.cgh.2026.06.008_bib33","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/j.cgh.2020.10.039","article-title":"Contemporary risk of surgery in patients with ulcerative colitis and Crohn's disease: a meta-analysis of population-based cohorts","volume":"19","author":"Tsai","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.06.008_bib34","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/j.cgh.2023.08.034","article-title":"Use of DPP4 inhibitors and GLP-1 receptor agonists and risk of intestinal obstruction: Scandinavian cohort study","volume":"22","author":"Ueda","year":"2024","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356526004428?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356526004428?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:02:01Z","timestamp":1785974521000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356526004428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":34,"alternative-id":["S1542356526004428"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2026.06.008","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjunctive GLP1 Receptor Agonists in Patients With Inflammatory Bowel Diseases and Obesity and\/or Diabetes: A Target Trial Emulation","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2026.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Gastroenterological Association Institute. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}